Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | ifinatamab deruxtecan (I-DXd) - (IDeate-Esophageal01) | Advanced or metastatic esophageal squamous cell carcinoma (ESCC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Merck & Company Inc. | Zilovertamab Vedotin - (waveLINE-010) | Untreated Diffuse Large B-Cell Lymphoma | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Combination with Chemotherapy - (LEAP-015) | Gastroesophageal Adenocarcinoma | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) plus chemotherapy - (KEYLYNK-001) | Advanced Epithelial Ovarian Cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | LAGEVRIO (molnupiravir) - (MOVe-NOW) | COVID-19 in High-Risk Adults | Phase 3 | Enrollment Initiation | Oral | COVID-19 |
| Merck & Company Inc. | V940 (mRNA-4157) + KEYTRUDA (pembrolizumab) - (INTerpath-009) | Non-small cell lung cancer (NSCLC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Merck & Company Inc. | Tulisokibart (MK-7240) - (ARES-CD) | Crohn's disease (CD) | Phase 3 | Enrollment Initiation | Oral | Gastroenterology |
| Merck & Company Inc. | Tulisokibart (MK-7240) - (ATLAS-UC) | Ulcerative colitis (UC) | Phase 3 | Enrollment Initiation | Oral | Gastroenterology |
